Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-20
2007-11-20
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
10536382
ABSTRACT:
A luminescent lanthanide complex using a photo induced electron transfer as the luminescence controlling principle is presented. The complex comprises a substituted 2-quinolinol containing a sensor group and a complex group and lanthanide ion (Ln3+). This complex is allowed to be co-present in a liquid phase with a material to be measured, and the luminescence of said complex is measured.
REFERENCES:
patent: 2616855 (1952-11-01), Wheelock
patent: 6277841 (2001-08-01), Rajagopalan et al.
Zaharevitz, et al., “Discovery of novel HIV-1 reverse transcriptase inhibitors . . . ”, Medicinal Chemistry Research 1999 vol. 9 (7/8) p. 551-564.
Iwasawa Shinya
Kikuchi Kazuya
Nagano Tetsuo
Gary C Cohn PLLC
Hartley Michael G.
Japan Science and Technology Agency
Samala Jagadishwar
LandOfFree
Fluorescent lanthadine complex does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorescent lanthadine complex, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorescent lanthadine complex will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3825166